sonelokimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
sonelokimab

GtoPdb Ligand ID: 10491

Synonyms: IL17-MS3086 | IL17MS3086 | M-1095 | M1095 | MSB-0010841 | MSB0010841 | SEQ ID 836 [WO2012156219A1]

Compound class: Antibody

Comment: Sonelokimab (MSB0010841; M1095) is an anti-IL-17A/F single chain camelid nanobody [1]. The peptide sequence for proposed INN sonelokimab is a 100% match for SEQ ID 836 that is claimed in Merck/Ablynx patent WO2012156219A1. Sonelokimab potently binds to both IL-17A and -F and prevents IL-17R pathway activation (e.g . IL-6 production), and was designed for anti-inflammatory potential.

References
1. Bruniquel D, Chavalet L, Chvatchko Y, Kilkman JA, Leger O, Proudfoot AEI, Rommelaere H, Saunders MJS, Union A, Vicari A. (2012) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same. Patent number: WO2012156219A1. Assignee: Ablynx Nv, Merck Patent Gmbh. Priority date: 05/05/2011. Publication date: 22/11/2012.
2. Dogra S, Singh S. (2025) Assessing the clinical progress of the bispecific nanobody sonelokimab. Expert Opin Investig Drugs, 34 (4): 253-258. [PMID:40297934]
3. Papp KA, Weinberg MA, Morris A, Reich K. (2021) IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet, 397 (10284): 1564-1575. [PMID:33894834]
4. Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. (2019) A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol, 81 (1): 196-203. [PMID:30926369]

References

1. Bruniquel D, Chavalet L, Chvatchko Y, Kilkman JA, Leger O, Proudfoot AEI, Rommelaere H, Saunders MJS, Union A, Vicari A. (2012)
Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same.
Patent number: WO2012156219A1. Assignee: Ablynx Nv, Merck Patent Gmbh. Priority date: 05/05/2011. Publication date: 22/11/2012.

2. Dogra S, Singh S. (2025)
Assessing the clinical progress of the bispecific nanobody sonelokimab.
Expert Opin Investig Drugs, 34 (4): 253-258. [PMID:40297934]

3. Papp KA, Weinberg MA, Morris A, Reich K. (2021)
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Lancet, 397 (10284): 1564-1575. [PMID:33894834]

4. Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. (2019)
A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.
J Am Acad Dermatol, 81 (1): 196-203. [PMID:30926369]